Institute for Quality and Efficiency in Health Care
Telaprevir: Added benefit in certain patients with hepatitis C
The drug telaprevir (trade name: Incivo) has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for ...
Diseases, Conditions, Syndromes
Sep 05, 2012 |
not rated yet |
0
Belimumab for lupus erythematosus: Added benefit not proven
Belimumab (trade name Benlysta) has been approved since July 2011 as an add-on therapy for adult patients with the autoimmune disease systemic lupus erythematosus (SLE). This monoclonal antibody is only considered as treatment ...
Cancer
Aug 29, 2012 |
not rated yet |
0
Added benefit of fampridine is not proven
Fampridine (trade name Fampyra) has been approved in Germany since July 2011 for adult patients suffering from a higher grade walking disability (grades 4 to 7 on the EDSS disability status scale), as a result of multiple ...
Medications
Aug 29, 2012 |
not rated yet |
0
Added benefit of eribulin in breast cancer is not proven
Eribulin (trade name: Halaven) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.
Cancer
Aug 16, 2012 |
not rated yet |
0
Benefit of PET and PET/CT in ovarian cancer is not proven
Due to the lack of studies, there is currently no proof that patients with ovarian cancer can benefit from positron emission tomography (PET) alone or in combination with computed tomography (CT). As regards diagnostic accuracy, ...
Cancer
Aug 08, 2012 |
not rated yet |
0
DMP module on heart failure: Current guidelines indicate some need for revision
The German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with heart failure. The aim of ...
Cardiology
Aug 01, 2012 |
not rated yet |
0
Obesity in type 2 diabetes: Recommendations from guidelines are largely consistent
On 10th July 2012, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based guidelines for the treatment of obesity in type 2 diabetes. The aim ...
Diabetes
Jul 30, 2012 |
5 / 5 (1) |
0
Collagenase for Dupuytren's contracture: Added benefit not proven
Collagenase extracted from Clostridium histolyticum (trade name: Xiapex) was approved in the beginning of 2011 for the treatment of people with Dupuytren's contracture. In an early benefit assessment pursuant to the "Act ...
Diseases, Conditions, Syndromes
Jul 12, 2012 |
not rated yet |
0
Fingolimod: 'Hint' of advantages in a small group of patients
The immunosuppressive drug fingolimod (trade name: Gilenya) is approved for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in adults. In an early benefit assessment pursuant to "Act on the Reform ...
Diseases, Conditions, Syndromes
Jul 05, 2012 |
not rated yet |
0
- Pages: 1 2
